IL99874A - Aminoglycoside preparation with significantly reduced toxicity to the kidneys caused by the amino glycoside and xanthine proliferation - Google Patents

Aminoglycoside preparation with significantly reduced toxicity to the kidneys caused by the amino glycoside and xanthine proliferation

Info

Publication number
IL99874A
IL99874A IL9987491A IL9987491A IL99874A IL 99874 A IL99874 A IL 99874A IL 9987491 A IL9987491 A IL 9987491A IL 9987491 A IL9987491 A IL 9987491A IL 99874 A IL99874 A IL 99874A
Authority
IL
Israel
Prior art keywords
group
compound
aminoglycoside
formula
carbon atoms
Prior art date
Application number
IL9987491A
Other languages
English (en)
Hebrew (he)
Other versions
IL99874A0 (en
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of IL99874A0 publication Critical patent/IL99874A0/xx
Publication of IL99874A publication Critical patent/IL99874A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
IL9987491A 1990-10-30 1991-10-28 Aminoglycoside preparation with significantly reduced toxicity to the kidneys caused by the amino glycoside and xanthine proliferation IL99874A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/606,018 US5039666A (en) 1990-10-30 1990-10-30 Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside

Publications (2)

Publication Number Publication Date
IL99874A0 IL99874A0 (en) 1992-08-18
IL99874A true IL99874A (en) 1995-08-31

Family

ID=24426160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9987491A IL99874A (en) 1990-10-30 1991-10-28 Aminoglycoside preparation with significantly reduced toxicity to the kidneys caused by the amino glycoside and xanthine proliferation

Country Status (16)

Country Link
US (1) US5039666A (ko)
EP (1) EP0483634B1 (ko)
JP (1) JP3003333B2 (ko)
KR (1) KR0139199B1 (ko)
AT (1) ATE133072T1 (ko)
AU (1) AU640056B2 (ko)
CA (1) CA2054471C (ko)
DE (1) DE69116503T2 (ko)
DK (1) DK0483634T3 (ko)
ES (1) ES2083500T3 (ko)
GR (1) GR3018824T3 (ko)
HU (1) HU213509B (ko)
IE (1) IE70670B1 (ko)
IL (1) IL99874A (ko)
PT (1) PT99358B (ko)
ZA (1) ZA918592B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT584347E (pt) * 1992-03-04 2003-06-30 Cell Therapeutics Inc Compostos de xantina hidroxilados enantiomericos
JP3076672B2 (ja) * 1992-06-18 2000-08-14 三井化学株式会社 キノリン誘導体のフマル酸塩
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5340813A (en) * 1992-11-09 1994-08-23 Cell Therapeutics, Inc. Substituted aminoalkyl xanthine compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5473070A (en) * 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5866576A (en) * 1992-12-16 1999-02-02 Cell Therapeutics, Inc. Epoxide-containing compounds
WO1994015605A1 (en) * 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5837703A (en) * 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
WO1995022546A1 (en) * 1994-02-18 1995-08-24 Cell Therapeutics, Inc. Intracellular signalling mediators
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
DE19823396A1 (de) * 1998-05-26 1999-12-02 Bayer Ag Synergistische insektizide Mischungen
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
EA200501518A1 (ru) * 2003-03-26 2006-04-28 Ресептикон Апс Применение соединений для профилактики лекарственно-индуцированной клеточной токсичности
CN101076372A (zh) * 2004-10-06 2007-11-21 里斯普蒂康公司 化合物用于预防药物诱导的细胞毒性的用途
US7439343B2 (en) * 2005-09-01 2008-10-21 Rensselaer Polytechnic Institute Aminoglycoside-polyamine displacers and methods of use in displacement chromatography
WO2009152202A2 (en) * 2008-06-11 2009-12-17 Utah State University New aminoglycosides: synthesis and use as antifungals
WO2012082650A2 (en) 2010-12-14 2012-06-21 Utah State University Aminoglycosides:synthesis and use as antifungals
US9669044B2 (en) 2010-12-14 2017-06-06 Utah State University Aminoglycoside and azole compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029882A (en) * 1974-03-19 1977-06-14 Schering Corporation Selective acylation of the C-1 amino group of aminoglycoside antibiotics
US4002742A (en) * 1974-03-19 1977-01-11 Schering Corporation 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor
US4235892A (en) * 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
EP0414175A3 (en) * 1989-08-22 1992-04-01 Hoechst Aktiengesellschaft Use of xanthine derivatives to reduce nephrotoxicity

Also Published As

Publication number Publication date
ATE133072T1 (de) 1996-02-15
ZA918592B (en) 1992-07-29
AU640056B2 (en) 1993-08-12
GR3018824T3 (en) 1996-04-30
KR0139199B1 (ko) 1998-05-15
CA2054471A1 (en) 1992-05-01
JP3003333B2 (ja) 2000-01-24
DE69116503T2 (de) 1996-06-20
IE913775A1 (en) 1992-05-22
DK0483634T3 (da) 1996-05-20
IL99874A0 (en) 1992-08-18
JPH04282315A (ja) 1992-10-07
HUT60136A (en) 1992-08-28
KR920007630A (ko) 1992-05-27
IE70670B1 (en) 1996-12-11
PT99358A (pt) 1992-09-30
US5039666A (en) 1991-08-13
PT99358B (pt) 1999-03-31
EP0483634B1 (en) 1996-01-17
ES2083500T3 (es) 1996-04-16
EP0483634A2 (en) 1992-05-06
AU8680291A (en) 1992-05-07
HU913392D0 (en) 1992-01-28
DE69116503D1 (de) 1996-02-29
HU213509B (en) 1997-07-28
CA2054471C (en) 1998-09-22
EP0483634A3 (en) 1992-10-14

Similar Documents

Publication Publication Date Title
AU640056B2 (en) An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside
AU2001291022B2 (en) Xanthine phosphodiesterase v inhibitors
KR20010032051A (ko) 퓨린유도체 및 이를 유효성분으로 함유하는 의약
WO2003020724A1 (en) Polycyclic guanine phosphodiesterase v inhibitors
HUT59825A (en) Process for producing immuno-inhibiting pharmaceutical compositions containijng xantine derivatives
PT89757B (pt) Processo para a preparacao de novos derivados da xantina e de composicoes farmaceuticas que os contem, uteis no tratamento da ulcera peptica
CZ288897B6 (cs) Fenanthridiniový derivát, farmaceutický prostředek jej obsahující a jeho použití
FI85481C (fi) Foerfarande foer framstaellning av 2,3 -dihydro-1-(8-metyl-1,2,4-triazolo/4,3-b/pyridazin-6-yl)-4(1h) -pyridinon.
WO2024022520A1 (zh) 适用于抗体-药物偶联物的毒素分子
AU626295B2 (en) Imidazo(1,2-a)furo-and thieno pyridine derivatives
JPH05294966A (ja) キサンチン誘導体
AU716997B2 (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
JPH0324081A (ja) ７Ｈ―ベンゾ〔ｂ〕ピラジノ〔１，２‐ｄ〕ピロロ〔３，２，１―ｊｋ〕〔１，４〕ベンゾジアゼピンおよびその製法
EP1790652A1 (en) Polycyclic guanine phosphodiesterase V inhibitors

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees